X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.prnewswire.com/news-releases/ryvu-announces-dosing-of-the-first-patient-in-the-river-81-phase-ii-study-of-rvu120-in-combination-with-venetoclax-for-the-treatment-of-patients-with-relapsedrefractory-aml-302049728.html
https://www.globenewswire.com//news-release/2024/01/07/2805016/0/en/Vincerx-Pharma-Announces-Compelling-Clinical-Efficacy-of-Enitociclib-in-Combination-with-Venetoclax-and-Prednisone-in-Lymphoma.html
https://www.fiercepharma.com/pharma/ash-after-pulling-approvals-april-abbvie-plots-imbruvica-comeback-mantle-cell-lymphoma
https://www.globenewswire.com//news-release/2023/12/11/2793570/0/en/New-Data-Presented-at-ASH-from-the-Phase-3-GLOW-Study-Show-Fixed-Duration-First-Line-Treatment-with-IMBRUVICA-ibrutinib-Plus-Venetoclax-Demonstrated-an-Overall-Survival-Rate-of-Mor.html
https://www.prnewswire.com/news-releases/abbvie-presents-results-from-phase-3-canova-study-of-venetoclax-in-patients-with-relapsed-or-refractory-multiple-myeloma-301942538.html
https://www.onclive.com/view/venetoclax-atezolizumab-obinutuzumab-elicits-durable-responses-in-richter-transformation
https://investor.seagen.com/press-releases/news-details/2023/Phase-3-Trial-of-ADCETRIS-brentuximab-vedotin-with-Modified-Chemo-Regimen-Shows-Non-Inferiority-with-Unprecedented-3-Year-Progression-Free-Survival-of-94.9-vs-Less-Tolerable-International-Standard-of-Care-in-Advanced-Classical-Hodgkin-Lymphoma/default.aspx
https://www.onclive.com/view/zanubrutinib-plus-obinutuzumab-and-venetoclax-induces-high-undetectable-mrd-rate-in-cll-sll
https://www.onclive.com/view/ibrutinib-obinutuzumab-venetoclax-triplet-elicits-sustained-clinical-benefit-in-mantle-cell-lymphoma
https://www.prnewswire.com/news-releases/abbvies-venclyxtovenclexta-venetoclax-continues-to-show-sustained-progression-free-survival-pfs-in-chronic-lymphocytic-leukemia-cll-patients-301846690.html
https://www.fiercepharma.com/pharma/beigenes-brukinsa-surging-cll-abbvie-gets-win-uk-imbruvica-venclyxta-combo
https://www.pharmiweb.com/press-release/2023-04-21/nice-gives-green-light-to-ibrutinib-plus-venetoclax-as-first-line-treatment-option-for-chronic-lymphocytic-leukaemia
https://www.fiercebiotech.com/biotech/fda-puts-curis-leukemia-trial-partial-hold-after-patient-death-spurs-review-muscle
https://www.globenewswire.com//news-release/2022/12/12/2572030/0/en/ALX-Oncology-Announces-Initial-Data-from-ASPEN-05-Study-of-Evorpacept-in-Combination-with-Azacitidine-and-Venetoclax-Demonstrating-Tolerability-and-Preliminary-Activity-in-Patients.html
https://www.accesswire.com/731275/100-Clinical-Benefit-Rate-Achieved-in-Phase-1b-Trial-Evaluating-APVO436-in-Combination-with-Venetoclax-and-Azacitidine-for-Venetoclax-Treatment-Nave-Patients-with-Acute-Myeloid-Leukemia-AML
https://www.globenewswire.com/news-release/2022/12/11/2571432/0/en/Kymera-Therapeutics-Presents-Preclinical-Data-Demonstrating-Activity-of-KT-253-a-Selective-Heterobifunctional-MDM2-Degrader-in-Acute-Myeloid-Leukemia-at-the-American-Society-of-Hem.html
https://www.prnewswire.com/news-releases/new-results-from-the-phase-3-glow-study-of-fixed-duration-treatment-with-imbruvica-ibrutinib-plus-venetoclax-demonstrate-robust-efficacy-and-sustained-response-in-older-unfit-patients-with-previously-untreated-chronic-lymphocy-301699746.html
https://www.globenewswire.com//news-release/2022/11/30/2565433/0/en/Imago-BioSciences-Announces-First-Participant-Dosed-in-Investigator-Sponsored-Phase-1-Study-of-Bomedemstat-in-Combination-with-Venetoclax-in-Relapsed-Refractory-Acute-Myeloid-Leuke.html
https://www.prnewswire.com/news-releases/biosight-launches-a-phase-12-clinical-trial-of-aspacytarabine-in-combination-with-venetoclax-for-first-line-aml-induction-therapy-followed-by-aspacytarabine-consolidation-301685067.html
https://endpts.com/abbvie-calls-off-phi-trial-for-i-mabs-cd47-days-after-zai-lab-shelves-its-own-program/
http://www.pharmafile.com/news/637320/smc-accepts-chemotherapy-free-venclyxto-leukaemia-treatment
https://www.globenewswire.com/news-release/2022/04/12/2420813/10564/en/Cyclacel-Pharmaceuticals-Announces-Publication-Confirming-Fadraciclib-Suppresses-MCL1-and-Synergizes-With-Venetoclax-in-Chronic-Lymphocytic-Leukemia.html
https://www.globenewswire.com/news-release/2022/04/11/2420006/32092/en/Zosano-Pharma-Announces-Reverse-Stock-Split-Effective-Today.html
https://www.pharmatimes.com/news/nice_recommend_venetoclax_and_azacytidine_for_patients_with_aggressive_blood_cancer_1385470
https://www.mdanderson.org/newsroom/venetoclax-combination-therapies-found-effective-against-challenging-subtypes-of-acute-myeloid-leukemia.h00-159466368.html
https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-inc-announces-greater-difference-of-approximately-5x-for-iomab-b-vs-control-arm-in-the-number-of-patients-potentially-evaluable-for-the-primary-endpoint-of-the-pivotal-phase-3-sierra-trial-at-the-63rd-as-301442794.html
https://www.globenewswire.com/news-release/2021/12/09/2349194/0/en/Aprea-Therapeutics-Announces-Removal-of-FDA-Clinical-Hold-on-Eprenetapopt-in-Lymphoid-Malignancies.html
https://www.fiercebiotech.com/biotech/fda-slaps-clinical-hold-astrazeneca-cancer-drug-amid-heart-safety-scare-combo-test
https://www.cancertherapyadvisor.com/home/news/conference-coverage/eha2021-virtual-congress/chronic-leukemia-cll-ibrutinib-venetoclax-therapy-improve-outcome/
https://news.abbvie.com/news/press-releases/imbruvica-ibrutinib-plus-venclextavenclyxto-venetoclax-combination-shows-superior-progression-free-survival-compared-to-chlorambucil-plus-obinutuzumab-in-first-line-chronic-lymphocytic-leukemia-cll-phase-3-glow-study.htm
https://www.prnewswire.com/news-releases/imbruvica-ibrutinib-plus-venclextavenclyxto-venetoclax-combination-shows-superior-progression-free-survival-compared-to-chlorambucil-plus-obinutuzumab-in-first-line-chronic-lymphocytic-leukemia-cll-phase-3-glow-study-301311176.html
https://www.prnewswire.com/news-releases/european-hematology-association--first-line-ibrutinib--venetoclax-is-superior-to-chlorambucil--obinutuzumab-for-chronic-lymphocytic-leukemiasmall-lymphocyte-lymphoma-301310009.html
https://www.pharmatimes.com/news/mhra_approves_venclyxto_for_newly_diagnosed_aml_1371522
http://www.pharmafile.com/news/579591/mhra-approves-venetoclax-acute-myeloid-leukemia-treatment
http://www.pharmafile.com/news/579591/mhra-approves-venetoclax-acute-myeloid-leukemia-treatment
https://www.fiercepharma.com/pharma/abbvie-j-j-pad-imbruvica-s-cll-case-venclexta-fixed-duration-combo-7-year-monotherapy-data
Market Place
Share 
